Real question is, why not? The pre-clinical data is excellent and so what evidence is there to support a view that TT-034 will not prove to be efficacious at a clinical dose?
- Forums
- ASX - By Stock
- BLT
- Ann: SAN FRANCISCO BIOTECH PRESENTATION
Ann: SAN FRANCISCO BIOTECH PRESENTATION, page-16
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online